Key statistics
On Wednesday, ALX Oncology Holdings Inc (ALXO:NSQ) closed at 1.62, 3.85% above its 52-week low of 1.56, set on Oct 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.68 |
---|---|
High | 1.68 |
Low | 1.59 |
Bid | 1.59 |
Offer | 1.64 |
Previous close | 1.65 |
Average volume | 456.52k |
---|---|
Shares outstanding | 52.67m |
Free float | 41.96m |
P/E (TTM) | -- |
Market cap | 86.91m USD |
EPS (TTM) | -3.64 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 21:00 BST.
More ▼
Announcements
- ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
- ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
- ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
- ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
- ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
- ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
- ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
- ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
- ALX Oncology Appoints Allison Dillon as Chief Business Officer
More ▼